- Home
- STEC vs NRXP Comparison
STEC vs NRXP Comparison
Compare STEC & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STEC
- NRXP
- Stock Information
- Founded
- STEC 2006
- NRXP 2015
- Country
- STEC Hong Kong
- NRXP United States
- Employees
- STEC N/A
- NRXP N/A
- Industry
- STEC
- NRXP Biotechnology: Pharmaceutical Preparations
- Sector
- STEC
- NRXP Health Care
- Exchange
- STEC NYSE
- NRXP Nasdaq
- Market Cap
- STEC 63.8M
- NRXP 58.5M
- IPO Year
- STEC 2021
- NRXP N/A
- Fundamental
- Price
- STEC $0.74
- NRXP $2.81
- Analyst Decision
- STEC
- NRXP Strong Buy
- Analyst Count
- STEC 0
- NRXP 4
- Target Price
- STEC N/A
- NRXP $28.50
- AVG Volume (30 Days)
- STEC 10.9K
- NRXP 134.9K
- Earning Date
- STEC 08-05-2025
- NRXP 08-13-2025
- Dividend Yield
- STEC N/A
- NRXP N/A
- EPS Growth
- STEC N/A
- NRXP N/A
- EPS
- STEC N/A
- NRXP N/A
- Revenue
- STEC $10,672,000.00
- NRXP N/A
- Revenue This Year
- STEC $9,392.20
- NRXP N/A
- Revenue Next Year
- STEC N/A
- NRXP $230.95
- P/E Ratio
- STEC N/A
- NRXP N/A
- Revenue Growth
- STEC N/A
- NRXP N/A
- 52 Week Low
- STEC $0.20
- NRXP $1.10
- 52 Week High
- STEC $3.25
- NRXP $6.01
- Technical
- Relative Strength Index (RSI)
- STEC 40.44
- NRXP 35.57
- Support Level
- STEC $0.70
- NRXP $2.89
- Resistance Level
- STEC $0.80
- NRXP $3.15
- Average True Range (ATR)
- STEC 0.08
- NRXP 0.14
- MACD
- STEC 0.00
- NRXP -0.04
- Stochastic Oscillator
- STEC 38.55
- NRXP 7.27
About STEC SANTECH HOLDINGS LIMITED
Santech Holdings Ltd is a technology company focusing on exploring various opportunities in consumer technology, consumer healthcare and enterprise technology. It has two revenue segments Wealth management service and Asset management service. Key revenue is generated from Wealth management service.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.